Abstract: Methods and devices for maintaining a desired therapeutic drug effect over a prolonged therapy period are provided. In particular, oral dosage forms that release drug within the gastrointestinal tract at an ascending release rate over an extended time period are provided. The dosage forms may additionally comprise an immediate-release dose of drug.

Abstract: Disclosed are substances, compositions, dosage forms and methods relating to drugs including 3-aminopropyl-n-butyl-phosphinic acid; structural homologs thereof; 3-aminopropyl-n-butyl-phosphinic acid complexes; complexes that comprise structural homologs of 3-aminopropyl-n-butyl-phosphinic acid; pharmaceutically acceptable salts of 3-aminopropyl-n-butyl-phosphinic acid or structural homologs thereof; and mixtures of the above.

Abstract: This invention relates to novel formulations and methods for the controlled release delivery of topiramate; as well as to the use of these formulations and methods for treating disease.

Abstract: The present invention is directed to a dosage form configured to provide the controlled release of an active agent formulation. A dosage form according to the present invention includes a reservoir containing an active agent formulation and an engine positioned at least partially within the reservoir. In order to reduce the possibility that the engine included in a dosage form of the present invention will separate from the reservoir either during or after fabrication of the dosage form of the present invention, the engine included in a dosage form according to the present invention is bonded to an inside surface of the reservoir. The present invention also includes methods for preparing a controlled release dosage form.

Abstract: The present invention relates to osmotic engines and dosage forms providing the controlled release of a liquid active agent formulation. More specifically, the present invention is directed to osmotic engines, dosage forms and methods that preserve osmotic engine functionality and reduce void volume formation in osmotically driven dosage form providing the controlled release of liquid active agent formulations.

Abstract: Methods and devices for maintaining a desired therapeutic drug effect over a prolonged therapy period are provided. In particular, oral dosage forms that release drug within the gastrointestinal tract at an ascending release rate over an extended time period are provided. The dosage forms may additionally comprise an immediate-release dose of drug.

Abstract: Methods and devices for maintaining a desired therapeutic drug effect over a prolonged therapy period are provided. In particular, oral dosage forms that release drug within the gastrointestinal tract at an ascending release rate over an extended time period are provided. The dosage forms may additionally comprise an immediate-release dose of drug.

Abstract: Dosage forms and devices for enhancing controlled delivery of lowly soluble active agents including topiramate by use of a drug core composition that increases the solubility of the pharmaceutical agent are described. The present invention provides a drug core composition for delivering high doses of lowly soluble topiramate in solid oral drug delivery systems that are convenient to swallow, for once-a-day administration. The drug core composition contains topiramate, a surfactant and a carrier in ratios for optimal solubility and delivery.

Abstract: Dosage forms and devices for enhancing controlled delivery of pharmaceutical agents by use of a drug core composition that increases the solubility of the pharmaceutical agent are described. The present invention provides a means of delivering high doses of lowly soluble drug in oral drug delivery systems that are convenient to swallow, for once-a-day administration.

Abstract: The present invention discloses a method or process for enhancing skin lightening of one wash-off product relative to another wherein said method or process comprises using a composition which is less harsh (measured by zein solubility) relative to the other.

Abstract: The invention disclosed pertains to a novel delivery system comprising an agent formulation and means for dispensing the agent formulation from the delivery system.

Abstract: The invention disclosed pertains to a novel delivery system comprising an agent formulation and means for dispensing the agent formulation from the delivery system.

Abstract: The present invention teaches liquid sunscreen compositions in which level of surfactant is higher than level at which the sunscreen component(s) are still soluble in the surfactant in which they are used; and which comprise minimal levels of cationic polymer. Combination of cationic polymer (especially preferred surfactants and at minimum levels) and minimal levels of sunscreen lead to compositions with minimal levels of deposition and minimal SPF. Further, the compositions also maintain good lather.

Abstract: The present invention teaches liquid sunscreen compositions in which level of surfactant is higher than level at which the sunscreen component(s) are still soluble in the surfactant in which they are used; and which comprise minimal levels of cationic polymer. Combination of cationic polymer (especially preferred surfactants and at minimum levels) and minimal levels of sunscreen lead to compositions with minimal levels of deposition and minimal SPF. Further, the compositions also maintain good lather.

Abstract: The invention disclosed pertains to a dosage form comprising an agent formulation comprising drug and pharmaceutical carrier of cooperating particle size and means for dispensing the agent formulation from the dosage form.